QHRD107

QHRD107 is an orally administered small molecule inhibitor that selectively targets cyclin-dependent kinase 9 (CDK9). It was initially developed by Changzhou Qianhong Biopharma. The drug exhibits potent cytotoxic effects across various human hematological malignancies and has demonstrated the ability to repress expression of anti-apoptotic proteins such as MCL1 in multiple cancer models, including chronic lymphocytic leukemia, ovarian cancer, acute leukemia, and diffuse large B-cell lymphoma. Its primary mechanism involves blocking CDK9 activity to disrupt gene transcription essential for cancer cell survival. Clinical studies have shown meaningful responses and tolerable toxicity in patients with relapsed or refractory acute myeloid leukemia (AML), both as monotherapy and in combination with venetoclax (a BCL-2 inhibitor) and azacitidine (a hypomethylating agent). As of 2024, its highest development phase is Phase 2 for AML[1][2][3][5][6][7].

Other names

CDK9 inhibitor QHRD-107CDK-9 inhibitor QHRD-107CDK 9 inhibitor QHRD-107